| Witteveen, Els |
| Recruiting | 4 | 330 | Europe | Macrogol Only Product in Oral Dose Form, Macrogol/electrolytes, Magnesium hydroxide 724mg, Magnesiumoxide | Amsterdam UMC, location VUmc, Leiden University Medical Center, University Medical Center Groningen, Radboud University Medical Center, Erasmus Medical Center, Spaarne Gasthuis, Rijnstate Hospital, Jeroen Bosch Ziekenhuis, Flevoziekenhuis, Martini Hospital Groningen, Haaglanden Medical Centre, Universitiy Medical Centre Utrecht UMCU The Netherlands, Groene Hart Ziekenhuis, Bernhoven Hospital, Isala, Antoni van Leeuwenhoekziekenhuis (AVL) Amsterdam | Constipation, Opioid-Induced | 12/25 | 12/25 | | |
| Erpecum, Karel v |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Venneman, Niels G |
DIA-PANC, NCT03469726: Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer |
|
|
| Recruiting | N/A | 465 | Europe | Contrast-enhanced Diffusion-weighted MRI | Radboud University Medical Center, Dutch Cancer Society | Pancreatic Neoplasms | 01/22 | 01/23 | | |
COBRA, NCT05750966: Short-course Antibiotics Vs Standard Course Antibiotics in Patients with Cholangitis |
|
|
| Recruiting | N/A | 440 | Europe | cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours), ceftriaxone, gentamicin, cefuroxim, ciprofloxacin, cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), ZonMw: The Netherlands Organisation for Health Research and Development | Cholangitis | 03/26 | 09/26 | | |
| Ramsey, Nick F |
| Recruiting | N/A | 2 | Europe | ECoG (electrocorticography) sensing, CortiCom-Utrecht assembly | UMC Utrecht, Johns Hopkins University | Locked-in Syndrome, Neuromuscular Diseases, Brainstem Stroke, Traumatic Brain Injury | 10/26 | 10/27 | | |
NCT02224469: First Study With a Brain Implant to Help Locked-in Patients Communicate at Home |
|
|
| Completed | N/A | 3 | Europe | ECoG (electrocorticography) sensing, Activa PC + S | UMC Utrecht | Locked-In Syndrome | 02/24 | 02/24 | | |
| Laheij, Robert JF |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
| Agostoni, Pierfrancesco |
| Recruiting | N/A | 400 | Europe | | Ziekenhuis Netwerk Antwerpen (ZNA) | Chronic Total Occlusion of Coronary Artery, Angina Pectoris | 12/21 | 12/22 | | |
| Completed | N/A | 100 | Europe | TAVI (Transcatheter Aortic Valve Implant), FLOWer Embolic Protection System, transcatheter embolic protection for TAVI procedures | AorticLab Srl, Meditrial Europe Ltd. | Aortic Valve Stenosis, Intracranial Embolism and Thrombosis | 06/23 | 06/23 | | |
NCT04029363: Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk |
|
|
| Recruiting | N/A | 120 | Europe, RoW | HighLife Transcatheter Mitral Valve Replacement | HighLife SAS, ICON plc | Mitral Regurgitation | 03/25 | 06/30 | | |
PROCTOR, NCT03805048: PeRcutaneous cOronary Intervention of Native Coronary arTery Versus Venous Bypass Graft in Patients With Prior CABG |
|
|
| Recruiting | N/A | 584 | Europe | Percutaneous coronary intervention | Amsterdam UMC, location VUmc | Coronary Artery Disease | 12/26 | 06/27 | | |
| Rha, Sun Young |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf | Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health | Gastro-Oesophageal Cancer | 06/25 | 06/26 | | |
| Active, not recruiting | 2 | 250 | Europe, Canada, Japan, US, RoW | zenocutuzumab (MCLA-128), bispecific, MCLA-128 | Merus N.V. | Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion | 12/26 | 12/26 | | |
NCT05512182: Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression |
|
|
| Withdrawn | 2 | 50 | RoW | Chemotherapy | Yonsei University | Recurrent/Advanced Gastric Cancer | 10/23 | 10/23 | | |
NCT05270889: Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial |
|
|
| Not yet recruiting | 2 | 50 | RoW | Tislelizumab+Zanidatamab | Yonsei University | HER2-positive Gastric Cancer | 06/24 | 06/24 | | |
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 74 | Canada, US, RoW | ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine | Jazz Pharmaceuticals | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | 07/25 | 07/25 | | |
HER-RAM, NCT04888663: Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer ( Study) |
|
|
| Active, not recruiting | 1/2 | 50 | RoW | Trastuzumab + Ramucirumab + Paclitaxel | Yonsei University | Recurrent/Metastatic Gastric Cancer | 09/21 | 09/21 | | |
NCT05400915: Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients |
|
|
| Completed | 1/2 | 27 | RoW | Variltinib, Paclitaxel | Yonsei University | Gastric Cancer | 12/21 | 06/22 | | |
NCT05529667: Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy. |
|
|
| Completed | 1/2 | 15 | RoW | INCB054828, Paclitaxel | Yonsei University | Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel | 08/23 | 08/23 | | |
NCT04592211: Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer |
|
|
| Recruiting | 1/2 | 71 | RoW | olaparib+pembrolizumab+paclitaxel | Yonsei University | Gastric Cancer Stage IV | 12/24 | 05/25 | | |
YH32367-101, NCT05523947: Clinical Trial of YH32367 in Patients with HER2 Positive Locally Advanced or Metastatic Solid Tumor |
|
|
| Recruiting | 1/2 | 137 | RoW | YH32367 | Yuhan Corporation | HER2-Positive Solid Tumor | 10/26 | 12/26 | | |
NCT04835896: Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer |
|
|
| Completed | 1/2 | 49 | RoW | M7824+paclitaxel | Yonsei University | Recurrent/Metastatic Gastric Cancer | 10/23 | 10/23 | | |
NCT05894824: T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Recruiting | 1/2 | 58 | RoW | T-Dxd(Trastuzmab deruxtecan), Ramucirumab, Enhertu, Cyramza | Yonsei University | Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer | 05/25 | 01/26 | | |
NCT05508737: Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer |
|
|
| Active, not recruiting | 1/2 | 75 | RoW | Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®), Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®) | Yonsei University | Gastric and Gastroesophageal Junction Adenocarcinoma | 05/25 | 12/25 | | |
NCT03821233: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers |
|
|
| Completed | 1 | 112 | Canada, US, RoW | ZW49 | Zymeworks BC Inc. | HER2-expressing Cancers | 09/24 | 10/24 | | |
| Recruiting | 1 | 260 | US, RoW | CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi® | Coherus Biosciences, Inc., Merck Sharp & Dohme LLC | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | 12/25 | 08/26 | | |
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer |
|
|
| Active, not recruiting | 1 | 70 | US, RoW | TORL-2-307-MAB | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 12/24 | 12/25 | | |
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer |
|
|
| Recruiting | 1 | 70 | US, RoW | TORL-2-307-ADC | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 01/26 | | |
NCT02951091: Biomarker-Integrated Umbrella, Advanced Gastric Cancer |
|
|
| Completed | N/A | 400 | RoW | biomarker screening | Yonsei University | Gastric Cancer | 12/21 | 03/24 | | |
| Recruiting | N/A | 80 | RoW | | Yonsei University | Advanced Gastric Cancer | 12/26 | 12/26 | | |
| Torrance, Helen |
| Recruiting | N/A | 1500 | Europe | | UMC Utrecht | Infertility | 01/22 | 01/23 | | |
| Hillegersberg, Richard van |
| Active, not recruiting | N/A | 210 | Europe | Open Gastrectomy, Laparoscopic Gastrectomy | UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development, Johnson & Johnson | Gastric Cancer | 11/18 | 12/23 | | |
| Recruiting | N/A | 20 | Europe | Laparoscopic ischemic conditioning followed by esophagectomy | UMC Utrecht, University Hospital of Cologne | Esophageal Cancer | 06/22 | 12/22 | | |
| Leiner, Tim |
iCORONARY, NCT04939207: Safety and Cost-efficiëncy of New Imaging Techniques in Patients Suspected of Coronary Artery Disease |
|
|
| Recruiting | N/A | 825 | Europe | CT-FFR, Angiography-derived FFR, Angiography with invasive FFR-measurements | St. Antonius Hospital, ZonMw: The Netherlands Organisation for Health Research and Development, UMC Utrecht | Coronary Artery Disease | 04/25 | 04/25 | | |
| Snijders, Tom |
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo | Chimerix | H3 K27M, Glioma | 08/26 | 08/26 | | |
|
|
| Not yet recruiting | N/A | 144 | Europe | Clinical management based on the index MRI and an additional [¹⁸F] FET PET scan | Veerle Ruijters, ZonMw: The Netherlands Organisation for Health Research and Development, Curium PET France | Glioblastoma, Radionecrosis of Brain | 12/27 | 12/27 | | |
| Belle, Eric Van |
| Recruiting | 4 | 2500 | Europe, RoW | Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care | CoreAalst BV, Insight Lifetech Co., Ltd. | Coronary Artery Disease, Acute Coronary Syndrome | 06/26 | 06/30 | | |
MESAMI2, NCT02462330: Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy |
|
|
| Completed | 2 | 39 | Europe | Autologous MSC from bone marrow, mesenchymal stem cells, Placebo comparator, Human Albumin | University Hospital, Toulouse | Chronic Myocardial Ischemia | 12/22 | 12/22 | | |
RESTO, NCT04268875: Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT |
|
|
| Completed | N/A | 307 | Europe | Optical Coherence Tomography (OCT) | University Hospital, Clermont-Ferrand, Abbott, Corelab ISIT | In-stent Restenosis | 12/22 | 12/22 | | |
PiCSO-AMI-V, NCT04958421: A Study to Evaluate Safety and Feasibility of PiCSO Therapy in Patients With ST Elevation Inferior Wall Myocardial Infarction. |
|
|
| Terminated | N/A | 25 | Europe | PiCSO Impulse System | Miracor Medical SA | STEMI - ST Elevation Myocardial Infarction, Inferior Wall Myocardial Infarction | 02/23 | 02/23 | | |
| Active, not recruiting | N/A | 2001 | Europe | QFR-based diagnostic strategy, FFR-based diagnostic strategy | Aarhus University Hospital Skejby, Medis Medical Imaging Systems | Coronary Artery Disease | 07/23 | 12/25 | | |
| Completed | N/A | 60 | Europe | VALVOSFT intervention | Cardiawave SA, QbD Clinical | Aortic Valve Calcification, Aortic Valve Stenosis | 08/23 | 07/24 | | |
| Recruiting | N/A | 20 | Europe | Topaz TTVR System | TRiCares | Tricuspid Regurgitation | 12/24 | 05/29 | | |
| Completed | N/A | 172 | Europe | FFR-guided PCI and TAVI, CABG and SAVR | Maatschap Cardiologie Zwolle, Medtronic | Aortic Stenosis, Multi Vessel Coronary Artery Disease, TAVI, CABG, PCI, Fractional Flow Reserve | 06/24 | 06/24 | | |
NCT02710435: REDUCER-I: An Observational Study of the Neovasc Reducer™ System |
|
|
| Active, not recruiting | N/A | 400 | Europe | Reducer System, Reducer | Neovasc Inc., Shockwave Medical, Inc. | Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina | 11/23 | 12/28 | | |
HighFLO, NCT04888247: Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve |
|
|
| Recruiting | N/A | 30 | Europe, RoW | CLARITY | HighLife SAS | Mitral Regurgitation | 12/25 | 02/31 | | |
| Recruiting | N/A | 768 | Europe, RoW | Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site. | Meril Life Sciences Pvt. Ltd. | Aortic Valve Stenosis | 03/24 | 12/33 | | |
NCT04029363: Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk |
|
|
| Recruiting | N/A | 120 | Europe, RoW | HighLife Transcatheter Mitral Valve Replacement | HighLife SAS, ICON plc | Mitral Regurgitation | 03/25 | 06/30 | | |
| Recruiting | N/A | 240 | Europe | Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score | Hospices Civils de Lyon | Severe Aortic Stenosis | 12/27 | 12/27 | | |
FAST III, NCT04931771: Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization |
|
|
| Recruiting | N/A | 2228 | Europe | vFFR guided revascularization, FFR guided revascularization | ECRI bv, Siemens Healthineers AG, Pie Medical Imaging | Coronary Artery Disease | 05/25 | 05/25 | | |
BEST, NCT05454150: Balloon-Expandable Versus Self-expanding Transcatheter Heart Valve for Treatment of Symptomatic Native Aortic Valve Stenosis |
|
|
| Recruiting | N/A | 1862 | Europe | balloon-expandable valve, self-expanding valve | University Hospital, Lille, Ministry of Health, France | Aortic Valve Stenosis | 07/25 | 07/25 | | |
| Recruiting | N/A | 150 | Europe, Canada, RoW | Elective redo transcatheter aortic valve implantation (redo-TAVI), redo-TAVI, redo-TAVR, Valve-in-Valve (ViV), TAV-in-TAV, TAVR-in-TAVR, Revalve | Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences | Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction, Prosthesis Failure | 09/25 | 12/26 | | |
| Recruiting | N/A | 944 | Europe | CT-ADP performed during TAVI procedure, No CT-ADP performed during TAVI procedure | University Hospital, Lille, Siemens Healthineers, France, Ministry of Health, France | Aortic Valve Stenosis, Aortic Valve Insufficiency | 12/25 | 12/25 | | |
MITRA-HR, NCT03271762: Multicentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery |
|
|
| Recruiting | N/A | 330 | Europe, RoW | percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW, MITRACLIP, cardiac surgery | Nantes University Hospital, Ministère de la Santé, Abbott | Mitral Regurgitation | 03/27 | 05/28 | | |
| Recruiting | N/A | 400 | Europe, Canada, US | Evolut R/PRO bioprosthesis, Edwards Sapien S3/Ultra bioprosthesis | Erasmus Medical Center | Valve Heart Disease | 05/26 | 05/26 | | |
| Punt, Kees |
| Recruiting | 2 | 220 | Europe | radioembolization, Standard of care first-line systemic therapy | UMC Utrecht, Dutch Colorectal Cancer Group | Colorectal Cancer Metastatic | 10/25 | 10/28 | | |
| Lee, Dong-Gun |
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study |
|
|
| Recruiting | 3 | 12000 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 09/26 | 09/26 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study |
|
|
| Recruiting | 3 | 274 | Europe, US, RoW | DAS181, Placebo, DAS181 COVID-19, DAS181 OL | Ansun Biopharma, Inc. | Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19 | 08/25 | 08/25 | | |
| Completed | 2 | 203 | Europe, US, RoW | Olorofim, F901318 | F2G Biotech GmbH, Iqvia Pty Ltd | Invasive Fungal Infections | 02/23 | 02/23 | | |
| Slooter, Arjen JC |
| Recruiting | N/A | 159 | Europe | transcranial alternating current stimulation (tACS), Sham transcranial alternating current stimulation (tACS) | A.J.C. Slooter, Radboud University Medical Center, HagaZiekenhuis | Delirium | 01/27 | 03/27 | | |
| Henry, Timothy D |
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure |
|
|
| Recruiting | 2 | 150 | US | AB-1002, Gene Therapy, NAN-101 | Asklepios Biopharmaceutical, Inc. | Congestive Heart Failure | 10/26 | 12/30 | | |
| Recruiting | 1 | 12 | US | 3 x 10e13vg NAN-101 | Asklepios Biopharmaceutical, Inc. | Congestive Heart Failure, Heart Failure, Heart Disease, Ischemic, Cardiovascular Diseases, Heart Failure, Systolic, Heart Failure，Congestive, Heart Arrhythmia, Heart Failure, Diastolic, Heart; Complications | 12/26 | 12/26 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
| Recruiting | N/A | 500 | US | Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire, Acetylcholine Provocation | Yale University, Abbott | Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography | 12/32 | 12/32 | | |
| Recruiting | N/A | 70 | US | | Gentuity, LLC | Coronary Artery Disease | 12/25 | 07/26 | | |
| Fauser, Bart CJ |
| Recruiting | N/A | 1500 | Europe | | UMC Utrecht | Infertility | 01/22 | 01/23 | | |
COLA, NCT02309047: The Cycle Disturbances, OLigomenorrhea and Amenorrhea () Study & Biobank |
|
|
| Recruiting | N/A | 5000 | Europe | | UMC Utrecht | Anovulation | 06/22 | 08/23 | | |
| Broekmans, Frank JM |
| Recruiting | N/A | 1500 | Europe | | UMC Utrecht | Infertility | 01/22 | 01/23 | | |
| Stella, Pieter |
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD) |
|
|
| Active, not recruiting | N/A | 178 | Europe, Canada, US | SAPIEN 3 THV, Optimal Heart Failure Therapy | Cardiovascular Research Foundation, New York, Cardialysis BV, Avania | Aortic Valve Stenosis | 02/23 | 02/25 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/25 | 12/25 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/28 | 12/28 | | |
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction |
|
|
| Not yet recruiting | 4 | 40 | US | fentanyl and Remimazolam | Indiana University, Indiana University Health | Dental Extraction | 01/26 | 03/26 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Terminated | 4 | 109 | US | Tamsulosin Hydrochloride | University of Massachusetts, Worcester, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 10/23 | 10/23 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
